Background Vosoritide is a recombinant C-type natriuretic peptide analogue that increases annualised growth velocity in children with achondroplasia aged 5–18 years. We aimed to assess the safety and efficacy of vosoritide in infants and children younger than 5 years
The Australian guidelines for the management of children with achondroplasia aimed to provide core care recommendations for families and clinicians, facilitate communication between specialist, local teams and families and support delivery of high-quality care. (Tofts et al, 2023)
This first International Consensus Statement was developed to facilitate the improvement and standardization of care for children and adults with achondroplasia worldwide, in order to optimise their clinical outcomes and quality of life. (Ravi et al, 2022)
This observational study was undertaken to collect baseline growth parameters in children with achondroplasia before enrollment to interventional trials of vosoritide, and to delineate the natural history of this condition. (Ravi et al, 2022)
This retrospective study reports contemporary rates of medical complications in an Australian population of children. (Armstrong et al, 2022)